Sonrai Analytics, an emerging Irish innovator in Artificial Intelligence (AI) data discovery, and California-based IV Bioholdings (IVBH), an innovative company focusing in the area of liquid biopsy, today announced a strategic partnership to accelerate early detection of diseases with poor clinical outcomes.
The partnership brings Sonrai’s cloud AI technology for discovering, developing and validating high-value biomarkers to IVBH’s commercial portfolio: Liquid Lung, HepGene and Mammogen. The collaboration will streamline the ability to identify, validate and productise novel biomarkers, for the effective early detection and subsequent actionable treatment of patients with progressive disease.
IVBH is a clinical-stage bio-platform company that conceives, creates and scales first-generation precision health solutions that improve the detection, diagnosis and treatment of disease. They have made commendable strides across multiple disease and cancer areas and have chosen to collaborate with Sonrai to help drive their ambitious clinical pipelines.
The effective collaboration will entail Sonrai’s development of novel algorithms applied to specific disease areas to solidify and validate signatures supporting IVBH’s expertise and lab-focussed validations. It will empower these new assays to become leading diagnostics for patients. IVBH have ambitious goals to make waves in this market, with the first clinical data readout expected for the genTRU-breast program this Summer. This will be followed closely by the lung cancer and NAFLD programs, with plans for reaching a commercial launch phase for all three programs by the end of 2023 and an eye toward future expansion across the IVBH offering.
“We are delighted to partner with IV Bioholdings as our key goals in making a difference within healthcare are aligned and Sonrai can assist with the discovery and journey of these biomarkers,” said Sonrai Founder-CEO Dr Darragh McArt.
“This focus aligned perfectly not just with the experience of the Sonrai team but also with the intentional design of Sonrai’s decentralised and highly flexible AI platform, making this partnership a very natural fit.”
“Digital analytics within precision medicine requires many facets today to discover and validate markers that will optimally define patient groups to receive the right treatment,” said IVBH Founder and CEO Marty Keiser.
“The collaboration with Sonrai closes the loop for us, providing IVBH with the dedicated data science, engineering and regulatory expertise — and the AI-powered solutions required to unlock maximum value from the IVBH platform — from R&D through commercialization,” added Keiser.
For more information about IVBH, visit ivbh.studio. For more information about Sonrai Analytics, visit sonraianalytics.com.
About Sonrai Analytics
Sonrai Analytics was founded in 2018 by Dr Darragh McArt and Dr Deva Senevirathne as a technology start-up within Healthcare and Precision Medicine domains, spun-out of Queen’s University Belfast. Sonrai’s AI Cloud technologies help Biotech companies with biomarker discovery, development, and delivery. Greatly streamlining the ability for precision medicine organisations to identify, validate and productise novel biomarkers, treatments or clinical algorithms with life-saving potential. For additional information, please visit: www.sonraianalytics.com
About IV BioHoldings (IVBH)
Driven by a deep and unwavering love for people and a relentless quest to replace sick-care with precision healthcare, Marty Keiser founded IV BioHoldings (IVBH) in 2018. IVBH is a bio platform company that conceives, creates and scales first-generation precision health solutions that radically improve the detection, diagnosis and treatment of disease. The company has successfully launched three bio startups: Liquid Lung, HepGene and Mammogen. These companies are focused on pulmonary disease, metabolic disease and women’s health, respectively. For more info: ivbh.studio